2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation

Journal of the Formosan Medical Association

Volumn 115, Issue 11, 2016, Pages 893-952

  Chiang, Chern En ^a   Wu, Tsu Juey ^b   Ueng, Kwo Chang ^c   Chao, Tze Fan ^a,b   Chang, Kuan Cheng ^d,e   Wang, Chun Chieh ^f   Lin, Yenn Jiang ^a,b   Yin, Wei Hsian ^a,g   Kuo, Jen Yuan ^h,i   Lin, Wei Shiang ^j   Tsai, Chia Ti ^k   Liu, Yen Bin ^k   Lee, Kun Tai ^l,m   Lin, Li Jen ⁿ   Lin, Lian Yu ^k   Wang, Kang Ling ^a   Chen, Yi Jen ^o,p   Chen, Mien Cheng ^f   Cheng, Chen Chuan ^q   Wen, Ming Shien ^f   Chen, Wen Jone ^k,r   Chen, Jyh Hong ^n,s   Lai, Wen Ter ^l,m   Chiou, Chuen Wang ^a,b   Lin, Jiunn Lee ^k   Yeh, San Jou ^f   Chen, Shih Ann ^a,b   more..

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^g CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^h MACKAY MEMORIAL HOSPITAL   (Taiwan)

ⁱ MACKAY MEDICAL COLLEGE   (Taiwan)

^j TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^k NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^l KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^m KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

ⁿ NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^o TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^p TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^q CHI MEI MEDICAL CENTER   (Taiwan)

^r Poh Ai Hospital   (Taiwan)

^s CHINA MEDICAL UNIVERSITY   (Taiwan)

more..

Author keywords

ablation; antiarrhythmic agents; anticoagulation; atrial fibrillation; non vitamin K antagonist oral anticoagulant; vitamin K antagonist

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIVITAMIN K; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRONEDARONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; ASIA; ATRIAL FIBRILLATION; BLEEDING; BRAIN ELECTROPHYSIOLOGY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVERSION; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE CLASSIFICATION; FOLLOW UP; GENETIC PREDISPOSITION; HEART ATRIUM APPENDAGE; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MEDICAL SOCIETY; PERCUTANEOUS CORONARY INTERVENTION; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; RECURRENT DISEASE; CARDIOLOGY; HEMORRHAGE; PROCEDURES; STROKE; TAIWAN;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOLOGY; CATHETER ABLATION; HEMORRHAGE; HUMANS; SOCIETIES, MEDICAL; STROKE; TAIWAN;

EID: 85000363073     PISSN: 09296646     EISSN: 18760821     Source Type: Journal    
DOI: 10.1016/j.jfma.2016.10.005     Document Type: Article

References (331)

1. 1 Lloyd-Jones, D.M., Wang, T.J., Leip, E.P., Larson, M.G., Levy, D., Vasan, R.S., et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110 (2004), 1042–1046.
2. 2 Heeringa, J., van der Kuip, D.A., Hofman, A., Kors, J.A., van Herpen, G., Stricker, B.H., et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 27 (2006), 949–953.
3. 3 Guo, Y., Tian, Y., Wang, H., Si, Q., Wang, Y., Lip, G.Y., Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest 147 (2015), 109–119.
4. 4 Chugh, S.S., Havmoeller, R., Narayanan, K., Singh, D., Rienstra, M., Benjamin, E.J., et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129 (2014), 837–847.
5. 5 Sanna, T., Diener, H.C., Passman, R.S., Di Lazzaro, V., Bernstein, R.A., Morillo, C.A., et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 370 (2014), 2478–2486.
6. 6 Andrade, J., Khairy, P., Dobrev, D., Nattel, S., The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res 114 (2014), 1453–1468.
7. 7 Asghar, O., Alam, U., Hayat, S.A., Aghamohammadzadeh, R., Heagerty, A.M., Malik, R.A., Obesity, diabetes and atrial fibrillation; epidemiology, mechanisms and interventions. Curr Cardiol Rev 8 (2012), 253–264.
8. 8 Wong, C.X., Brooks, A.G., Leong, D.P., Roberts-Thomson, K.C., Sanders, P., The increasing burden of atrial fibrillation compared with heart failure and myocardial infarction: a 15-year study of all hospitalizations in Australia. Arch Intern Med 172 (2012), 739–741.
9. 9 Gami, A.S., Hodge, D.O., Herges, R.M., Olson, E.J., Nykodym, J., Kara, T., et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 49 (2007), 565–571.
10. 10 Go, A.S., Hylek, E.M., Phillips, K.A., Chang, Y., Henault, L.E., Selby, J.V., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285 (2001), 2370–2375.
11. 11 Lip, G.Y., Brechin, C.M., Lane, D.A., The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest 142 (2012), 1489–1498.
12. 12 Dewland, T.A., Olgin, J.E., Vittinghoff, E., Marcus, G.M., Incident atrial fibrillation among Asians, Hispanics, blacks, and whites. Circulation 128 (2013), 2470–2477.
13. 13 Rodriguez, C.J., Soliman, E.Z., Alonso, A., Swett, K., Okin, P.M., Goff, D.C. Jr., et al. Atrial fibrillation incidence and risk factors in relation to race-ethnicity and the population attributable fraction of atrial fibrillation risk factors: the Multi-Ethnic Study of Atherosclerosis. Ann Epidemiol, 25, 2015 71–6, 76.e71.
14. 14 Tse, H.F., Wang, Y.J., Ahmed Ai-Abdullah, M., Pizarro-Borromeo, A.B., Chiang, C.E., Krittayaphong, R., et al. Stroke prevention in atrial fibrillation—an Asian stroke perspective. Heart Rhythm 10 (2013), 1082–1088.
15. 15 Miyasaka, Y., Barnes, M.E., Gersh, B.J., Cha, S.S., Bailey, K.R., Abhayaratna, W.P., et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114 (2006), 119–125.
16. 16 Krijthe, B.P., Kunst, A., Benjamin, E.J., Lip, G.Y., Franco, O.H., Hofman, A., et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 34 (2013), 2746–2751.
17. 17 Chien, K.L., Su, T.C., Hsu, H.C., Chang, W.T., Chen, P.C., Chen, M.F., et al. Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese. Int.J Cardiol. 139 (2010), 173–180.
18. 18 Lee, C.H., Liu, P.Y., Tsai, L.M., Tsai, W.C., Ho, M.T., Chen, J.H., et al. Characteristics of hospitalized patients with atrial fibrillation in Taiwan: a nationwide observation. Am J Med, 120, 2007 819 e811–7.
19. 19 Patel, N.J., Deshmukh, A., Pant, S., Singh, V., Patel, N., Arora, S., et al. Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning. Circulation 129 (2014), 2371–2379.
20. 20 Tsai, C.T., Lai, L.P., Kuo, K.T., Hwang, J.J., Hsieh, C.S., Hsu, K.L., et al. Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling. Circulation 117 (2008), 344–355.
21. 21 Tsai, C.T., Tseng, C.D., Hwang, J.J., Wu, C.K., Yu, C.C., Wang, Y.C., et al. Tachycardia of atrial myocytes induces collagen expression in atrial fibroblasts through transforming growth factor β1. Cardiovasc Res 89 (2011), 805–815.
22. 22 Haissaguerre, M., Jais, P., Shah, D.C., Takahashi, A., Hocini, M., Quiniou, G., et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339 (1998), 659–666.
23. 23 Pandit, S.V., Jalife, J., Rotors and the dynamics of cardiac fibrillation. Circ Res 112 (2013), 849–862.
24. 24 Narayan, S.M., Krummen, D.E., Shivkumar, K., Clopton, P., Rappel, W.J., Miller, J.M., Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) trial. J Am Coll Cardiol 60 (2012), 628–636.
25. 25 Lin, Y.J., Lo, M.T., Lin, C., Chang, S.L., Lo, L.W., Hu, Y.F., et al. Prevalence, characteristics, mapping, and catheter ablation of potential rotors in nonparoxysmal atrial fibrillation. Circ Arrhythm Electrophysiol 6 (2013), 851–858.
26. 26 Ellinor, P.T., Lunetta, K.L., Albert, C.M., Glazer, N.L., Ritchie, M.D., Smith, A.V., et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet 44 (2012), 670–675.
27. 27 Gudbjartsson, D.F., Arnar, D.O., Helgadottir, A., Gretarsdottir, S., Holm, H., Sigurdsson, A., et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 448 (2007), 353–357.
28. 28 Chang, S.H., Chang, S.N., Hwang, J.J., Chiang, F.T., Tseng, C.D., Lee, J.K., et al. Significant association of rs13376333 in KCNN3 on chromosome 1q21 with atrial fibrillation in a Taiwanese population. Circ J 76 (2012), 184–188.
29. 29 Lee, K.T., Yeh, H.Y., Tung, C.P., Chu, C.S., Cheng, K.H., Tsai, W.C., et al. Association of RS2200733 but not RS10033464 on 4q25 with atrial fibrillation based on the recessive model in a Taiwanese population. Cardiology 116 (2010), 151–156.
30. 30 Wang, K.L., Wu, C.H., Huang, C.C., Wu, T.C., Naditch-Brule, L., Steg, P.G., et al. Complexity of atrial fibrillation patients and management in Chinese ethnicity in routine daily practice: insights from the RealiseAF Taiwanese cohort. J Cardiol 64 (2014), 211–217.
31. 31 Chiang, C.E., Zhang, S., Tse, H.F., Teo, W.S., Omar, R., Sriratanasathavorn, C., Atrial fibrillation management in Asia: from the Asian expert forum on atrial fibrillation. Int J Cardiol 164 (2013), 21–32.
32. 32 Steg, P.G., Alam, S., Chiang, C.E., Gamra, H., Goethals, M., Inoue, H., et al. Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart 98 (2012), 195–201.
33. 33 Determinants of warfarin use and international normalized ratio levels in atrial fibrillation patients in Japan. Subanalysis of the J-RHYTHM Registry. Circ J 75 (2011), 2357–2362.
34. 34 Amerena, J., Chen, S.A., Sriratanasathavorn, C., Cho, J.G., Huang, D., Omar, R., et al. Insights into management of atrial fibrillation in Asia Pacific gained from baseline data from REgistry on cardiac rhythm disORDers (RecordAF-Asia Pacific [AP]) registry. Am J Cardiol 109 (2012), 378–382.
35. 35 Guo, Y., Apostolakis, S., Blann, A.D., Wang, H., Zhao, X., Zhang, Y., et al. Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation. Int J Cardiol 168 (2013), 904–909.
36. 36 Oldgren, J., Healey, J.S., Ezekowitz, M., Commerford, P., Avezum, A., Pais, P., et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation 129 (2014), 1568–1576.
37. 37 Siu, C.W., Lip, G.Y., Lam, K.F., Tse, H.F., Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong. Heart Rhythm 11 (2014), 1401–1408.
38. 38 Nieuwlaat, R., Capucci, A., Camm, A.J., Olsson, S.B., Andresen, D., Davies, D.W., et al. Atrial fibrillation management: a prospective survey in ESC Member Countries. Eur Heart J 26 (2005), 2422–2434.
39. 39 Le Heuzey, J.Y., Breithardt, G., Camm, J., Crijns, H., Dorian, P., Kowey, P.R., et al. The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. Am J Cardiol 105 (2010), 687–693.
40. 40 Steinberg, B.A., Holmes, D.N., Ezekowitz, M.D., Fonarow, G.C., Kowey, P.R., Mahaffey, K.W., et al. Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J 165 (2013), 622–629.
41. 41 Gamra, H., Murin, J., Chiang, C.E., Naditch-Brule, L., Brette, S., Steg, P.G., Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey. Arch Cardiovasc Dis 107 (2014), 77–87.
42. 42 Lip, G.Y.H., Laroche, C., Dan, G.A., Santini, M., Kalarus, Z., Rasmussen, L.H., et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) pilot general registry. Europace 16 (2014), 308–309.
43. 43 Kirchhof, P., Ammentorp, B., Darius, H., De Caterina, R., Le Heuzey, J.Y., Schilling, R.J., et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF). Europace 16 (2014), 6–14.
44. 44 Chiang, C.E., Naditch-Brule, L., Murin, J., Goethals, M., Inoue, H., O'Neill, J., et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 5 (2012), 632–639.
45. 45 Murin, J., Naditch-Brule, L., Brette, S., Chiang, C.E., O'Neill, J., Steg, P.G., Clinical characteristics, management, and control of permanent vs. nonpermanent atrial fibrillation: insights from the RealiseAF survey. PLoS One, 9, 2014, e86443.
46. 46 Jahangir, A., Lee, V., Friedman, P.A., Trusty, J.M., Hodge, D.O., Kopecky, S.L., et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation 115 (2007), 3050–3056.
47. 47 Potpara, T.S., Polovina, M.M., Licina, M.M., Marinkovic, J.M., Prostran, M.S., Lip, G.Y., Reliable identification of “truly low” thromboembolic risk in patients initially diagnosed with “lone” atrial fibrillation: the Belgrade atrial fibrillation study. Circ Arrhythm Electrophysiol 5 (2012), 319–326.
48. 48 Benjamin, E.J., Wolf, P.A., D'Agostino, R.B., Silbershatz, H., Kannel, W.B., Levy, D., Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98 (1998), 946–952.
49. 49 Wyse, D.G., Slee, A., Epstein, A.E., Gersh, B.J., Rocco, T. Jr., Vidaillet, H., et al. Alternative endpoints for mortality in studies of patients with atrial fibrillation: the AFFIRM study experience. Heart Rhythm 1 (2004), 531–537.
50. 50 Wolf, P.A., Abbott, R.D., Kannel, W.B., Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22 (1991), 983–988.
51. 51 Wang, T.J., Larson, M.G., Levy, D., Vasan, R.S., Leip, E.P., Wolf, P.A., et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107 (2003), 2920–2925.
52. 52 Ohsawa, M., Okayama, A., Okamura, T., Itai, K., Nakamura, M., Tanno, K., et al. Mortality risk attributable to atrial fibrillation in middle-aged and elderly people in the Japanese general population: nineteen-year follow-up in NIPPON DATA80. Circ J 71 (2007), 814–819.
53. 53 Zhou, Z., Hu, D., An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China. J Epidemiol 18 (2008), 209–216.
54. 54 Yap, K.B., Ng, T.P., Ong, H.Y., Low prevalence of atrial fibrillation in community-dwelling Chinese aged 55 years or older in Singapore: a population-based study. J Electrocardiol 41 (2008), 94–98.
55. 55 Tanizaki, Y., Kiyohara, Y., Kato, I., Iwamoto, H., Nakayama, K., Shinohara, N., et al. Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study. Stroke 31 (2000), 2616–2622.
56. 56 Camm, A.J., Breithardt, G., Crijns, H., Dorian, P., Kowey, P., Le Heuzey, J.Y., et al. Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation: RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). J Am Coll Cardiol 58 (2011), 493–501.
57. 57 Camm, A.J., Kirchhof, P., Lip, G.Y., Schotten, U., Savelieva, I., Ernst, S., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31 (2010), 2369–2429.
58. 58 Dorian, P., Jung, W., Newman, D., Paquette, M., Wood, K., Ayers, G.M., et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol 36 (2000), 1303–1309.
59. 59 Ware, J.E. Jr., Sherbourne, C.D., The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 (1992), 473–483.
60. 60 Rabin, R., de Charro, F., EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33 (2001), 337–343.
61. 61 Gallagher, M.M., Camm, A.J., Classification of atrial fibrillation. Pacing Clin Electrophysiol 20 (1997), 1603–1605.
62. 62 Levy, S., Classification system of atrial fibrillation. Curr Opin Cardiol 15 (2000), 54–57.
63. 63 Calkins, H., Kuck, K.H., Cappato, R., Brugada, J., Camm, A.J., Chen, S.A., et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm, 9, 2012 632–96.e621.
64. 64 Lubitz, S.A., Benjamin, E.J., Ruskin, J.N., Fuster, V., Ellinor, P.T., Challenges in the classification of atrial fibrillation. Nat Rev Cardiol 7 (2010), 451–460.
65. 65 Dorian, P., Guerra, P.G., Kerr, C.R., O'Donnell, S.S., Crystal, E., Gillis, A.M., et al. Validation of a new simple scale to measure symptoms in atrial fibrillation: the Canadian Cardiovascular Society Severity in Atrial Fibrillation scale. Circ Arrhythm Electrophysiol 2 (2009), 218–224.
66. 66 Kirchhof, P., Auricchio, A., Bax, J., Crijns, H., Camm, J., Diener, H.C., et al. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J 28 (2007), 2803–2817.
67. 67 Savelieva, I., Camm, A.J., Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 4 (2000), 369–382.
68. 68 Brignole, M., Vardas, P., Hoffman, E., Huikuri, H., Moya, A., Ricci, R., et al. Indications for the use of diagnostic implantable and external ECG loop recorders. Europace 11 (2009), 671–687.
69. 69 Hindricks, G., Pokushalov, E., Urban, L., Taborsky, M., Kuck, K.-H., Lebedev, D., et al. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation results of the XPECT Trial. Circ Arrhythm Electrophysiol 3 (2010), 141–147.
70. 70 Lin, C.T., Chang, K.C., Lin, C.L., Chiang, C.C., Lu, S.W., Chang, S.S., et al. An intelligent telecardiology system using a wearable and wireless ECG to detect atrial fibrillation. IEEE Trans Inf Technol Biomed 14 (2010), 726–733.
71. 71 Kamel, H., Navi, B.B., Elijovich, L., Josephson, S.A., Yee, A.H., Fung, G., et al. Pilot randomized trial of outpatient cardiac monitoring after cryptogenic stroke. Stroke 44 (2013), 528–530.
72. 72 Fuster, V., Ryden, L.E., Cannom, D.S., Crijns, H.J., Curtis, A.B., Ellenbogen, K.A., et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114 (2006), e257–e354.
73. 73 Healey, J.S., Parkash, R., Pollak, T., Tsang, T., Dorian, P., CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: etiology and initial investigations. Can J Cardiol 27 (2011), 31–37.
74. 74 Zabalgoitia, M., Halperin, J.L., Pearce, L.A., Blackshear, J.L., Asinger, R.W., Hart, R.G., Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol 31 (1998), 1622–1626.
75. 75 Chao, T.F., Liu, C.J., Wang, K.L., Lin, Y.J., Chang, S.L., Lo, L.W., et al. Using the CHA2DS2-VASc score for refining stroke risk stratification in ‘low-risk’ Asian patients with atrial fibrillation. J Am Coll Cardiol 64 (2014), 1658–1665.
76. 76 Friberg, L., Rosenqvist, M., Lip, G.Y.H., Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 33 (2012), 1500–1510.
77. 77 Lip, G.Y., Nieuwlaat, R., Pisters, R., Lane, D.A., Crijns, H.J., Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137 (2010), 263–272.
78. 78 Camm, A.J., Lip, G.Y., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S.H., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33 (2012), 2719–2747.
79. 79 Lin, L.Y., Lee, C.H., Yu, C.C., Tsai, C.T., Lai, L.P., Hwang, J.J., et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation—a nation wide database analysis. Atherosclerosis 217 (2011), 292–295.
80. 80 Chang, K.C., Wang, Y.C., Ko, P.Y., Wu, H.P., Chen, Y.W., Muo, C.H., et al. Increased risk of first-ever stroke in younger patients with atrial fibrillation not recommended for antithrombotic therapy by current guidelines: a population-based study in an East Asian cohort of 22 million people. Mayo Clin Proc 89 (2014), 1487–1497.
81. 81 Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
82. 82 Patel, M.R., Mahaffey, K.W., Garg, J., Pan, G., Singer, D.E., Hacke, W., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
83. 83 Granger, C.B., Alexander, J.H., McMurray, J.J., Lopes, R.D., Hylek, E.M., Hanna, M., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
84. 84 Giugliano, R.P., Ruff, C.T., Braunwald, E., Murphy, S.A., Wiviott, S.D., Halperin, J.L., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013), 2093–2104.
85. 85 Hori, M., Connolly, S.J., Zhu, J., Liu, L.S., Lau, C.P., Pais, P., et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 44 (2013), 1891–1896.
86. 86 Wong, K.S., Hu, D.Y., Oomman, A., Tan, R.S., Patel, M.R., Singer, D.E., et al. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. Stroke 45 (2014), 1739–1747.
87. 87 Goto, S., Zhu, J., Liu, L., Oh, B.H., Wojdyla, D.M., Aylward, P., et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J 168 (2014), 303–309.
88. 88 Koretsune, Y., Yamashita, T., Yang, Y., Chen, S.A., Chung, N., Giugliano, R.P., et al. Edoxaban versus warfarin in East-Asian (including Japanese) patients with atrial fibrillation—an ENGAGE AF-TIMI 48 sub-analysis. Circ J 78 (2014), I–484.
89. 89 Gage, B.F., Waterman, A.D., Shannon, W., Boechler, M., Rich, M.W., Radford, M.J., Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285 (2001), 2864–2870.
90. 90 Keogh, C., Wallace, E., Dillon, C., Dimitrov, B.D., Fahey, T., Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost 106 (2011), 528–538.
91. 91 Ogawa, S., Aonuma, K., Tse, H.F., Huang, D., Huang, J.L., Kalman, J., et al. The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. J Arrhythm 29 (2013), 190–200.
92. 92 January, C.T., Wann, L.S., Alpert, J.S., Calkins, H., Cigarroa, J.E., Cleveland, J.C., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130 (2014), 2071–2104.
93. 93 Center NCG, Atrial fibrillation: 2014, 1–418 http://guidance.nice.org.uk/CG/Wave0/638.
94. 94 Olesen, J.B., Lip, G.Y.H., Hansen, M.L., Hansen, P.R., Tolstrup, J.S., Lindhardsen, J., et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ, 342, 2011, d124.
95. 95 Chiang, C.E., Wang, K.L., Lip, G.Y., Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 111 (2014), 789–797.
96. 96 Huang, D.U.O., Anguo, L.U.O., Yue, W.S., Yin, L., Tse, H.F., Siu, C.W., Refinement of ischemic stroke risk in patients with atrial fibrillation and CHA2DS2-VASc score of 1. Pacing Clin Electrophysiol 37 (2014), 1442–1447.
97. 2-VASc and HAS-BLED Scores in Japanese Patients with nonvalvular atrial fibrillation; an analysis of the J-RHYTHM registry. Circ J 78 (2014), 1593–1599.
98. 98 Singer, D.E., Chang, Y., Borowsky, L.H., Fang, M.C., Pomernacki, N.K., Udaltsova, N., et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: The ATRIA study stroke risk score. J Am Heart Assoc, 2, 2013, e000250.
99. 99 GBD 2013 Mortality and Causes of Death Collaborators, Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385 (2015), 117–171.
100. 100 Chao, T.F., Wang, K.L., Liu, C.J., Lin, Y.J., Chang, S.L., Lo, L.W., et al. Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation: A Nationwide Cohort Study From Taiwan. J Am Coll Cardiol 66 (2015), 1339–1347.
101. 101 Gage, B.F., Yan, Y., Milligan, P.E., Waterman, A.D., Culverhouse, R., Rich, M.W., et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 151 (2006), 713–719.
102. 102 Fang, M.C., Go, A.S., Chang, Y., Borowsky, L.H., Pomernacki, N.K., Udaltsova, N., et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol 58 (2011), 395–401.
103. 103 Pisters, R., Lane, D.A., Nieuwlaat, R., de Vos, C.B., Crijns, H.J.G.M., Lip, G.Y.H., A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest 138 (2010), 1093–1100.
104. 104 Lip, G.Y.H., Frison, L., Halperin, J.L., Lane, D.A., Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 57 (2011), 173–180.
105. 105 Apostolakis, S., Lane, D.A., Guo, Y., Buller, H., Lip, G.Y.H., Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk–prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 60 (2012), 861–867.
106. 106 Roldán, V., Marín, F., Manzano-Fernández, S., Gallego, P., Vílchez, J.A., Valdés, M., et al. The HAS-BLED score has better prediction accuracy for major bleeding than cHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 62 (2013), 2199–2204.
107. 107 Naganuma, M., Shiga, T., Sato, K., Murasaki, K., Hashiguchi, M., Mochizuki, M., et al. Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin: A single-center observational study. Thromb Res 130 (2012), 21–26.
108. 108 Chan, K.H., Ka-Kit Leung, G., Lau, K.K., Liu, S., Lui, W.M., Lau, C.P., et al. Predictive value of the HAS-BLED score for the risk of recurrent intracranial hemorrhage after first spontaneous intracranial hemorrhage. World Neurosurg 82 (2014), e219–e223.
109. 109 Skanes, A.C., Healey, J.S., Cairns, J.A., Dorian, P., Gillis, A.M., McMurtry, M.S., et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 28 (2012), 125–136.
110. 110 Hart, R.G., Pearce, L.A., Aguilar, M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (2007), 857–867.
111. 111 Stroke Prevention in Atrial Fibrillation Study, Final results. Circulation 84 (1991), 527–539.
112. 112 Sato, H., Ishikawa, K., Kitabatake, A., Ogawa, S., Maruyama, Y., Yokota, Y., et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 37 (2006), 447–451.
113. 113 Friberg, L., Rosenqvist, M., Lip, G.Y., Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 125 (2012), 2298–2307.
114. 114 Ho, C.W., Ho, M.H., Chan, P.H., Hai, J.J., Cheung, E., Yeung, C.Y., et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. Stroke 46 (2015), 23–30.
115. 115 Connolly, S.J., Eikelboom, J., Joyner, C., Diener, H.C., Hart, R., Golitsyn, S., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 364 (2011), 806–817.
116. 116 Guo, Y., Pisters, R., Apostolakis, S., Blann, A.D., Wang, H., Zhao, X., et al. Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: would the novel oral anticoagulants have an impact?. Int J Cardiol 168 (2013), 515–522.
117. 117 Lin, L.J., Cheng, M.H., Lee, C.H., Wung, D.C., Cheng, C.L., Kao Yang, Y.H., Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation—a nationwide descriptive study in Taiwan. Clinical Therapeutics 30 (2008), 1726–1736.
118. 118 Fuster, V., Rydén, L.E., Asinger, R.W., Cannom, D.S., Crijns, H.J., Frye, R.L., et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 38 (2001), 1231–1265.
119. 119 Chang, C.H., Yang, Y.H., Chen, J.H., Lin, L.J., Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan. Thromb Res 133 (2014), 782–789.
120. 120 Connolly, S., Pogue, J., Hart, R., Pfeffer, M., Hohnloser, S., Chrolavicius, S., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367 (2006), 1903–1912.
121. 121 Connolly, S.J., Pogue, J., Hart, R.G., Hohnloser, S.H., Pfeffer, M., Chrolavicius, S., et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 360 (2009), 2066–2078.
122. 122 Mant, J., Hobbs, F.D.R., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G.Y.H., et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370 (2007), 493–503.
123. 123 Hylek, E.M., Skates, S.J., Sheehan, M.A., Singer, D.E., An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 335 (1996), 540–546.
124. 124 Hylek, E.M., Go, A.S., Chang, Y., Jensvold, N.G., Henault, L.E., Selby, J.V., et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349 (2003), 1019–1026.
125. 125 Baker, W.L., Cios, D.A., Sander, S.D., Coleman, C.I., Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 15 (2009), 244–252.
126. 126 Chan, H.T., So, L.T., Li, S.W., Siu, C.W., Lau, C.P., Tse, H.F., Effect of herbal consumption on time in therapeutic range of warfarin therapy in patients with atrial fibrillation. J Cardiovasc Pharmacol 58 (2011), 87–90.
127. 127 Wong, R.S., Cheng, G., Chan, T.Y., Use of herbal medicines by patients receiving warfarin. Drug Saf 26 (2003), 585–588.
128. 128 Apostolakis, S., Sullivan, R.M., Olshansky, B., Lip, G.Y., Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: The SAMe-TT2R2 score. Chest 144 (2013), 1555–1563.
129. 129 Larsen, T.B., Lip, G.Y.H., Warfarin or novel oral anticoagulants for atrial fibrillation?. The Lancet 383 (2014), 931–933.
130. 130 Poli, D., Antonucci, E., Testa, S., Lip, G.Y., A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med 9 (2014), 443–447.
131. 131 Lip, G.Y.H., Haguenoer, K., Saint-Etienne, C., Fauchier, L., Relationship of the SAMe-TT2R2 score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest 146 (2014), 719–726.
132. 132 Gallego, P., Roldán, V., Marin, F., Gálvez, J., Valdés, M., Vicente, V., et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 127 (2014), 1083–1088.
133. 133 Chan, P.H., Hai, J.J., Chan, E.W., Li, W.H., Tse, H.F., Wong, I.C., et al. Use of the SAMe-TT2R2 score to predict good anticoagulation control with warfarin in chinese patients with atrial fibrillation: relationship to ischemic stroke incidence. PLoS One, 11, 2016, e0150674.
134. 134 Hu, D., Sun, Y., Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coll Cardiol 52 (2008), 865–868.
135. 135 Shen, A.Y., Yao, J.F., Brar, S.S., Jorgensen, M.B., Chen, W., Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 50 (2007), 309–315.
136. 136 Teo, K.C., Mahboobani, N.R., Lee, R., Siu, C.W., Cheung, R.T., Ho, S.L., et al. Warfarin associated intracerebral hemorrhage in Hong Kong Chinese. Neurol Res 36 (2014), 143–149.
137. 137 Hylek, E.M., Singer, D.E., Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 120 (1994), 897–902.
138. 138 Husted, S., De Caterina, R., Andreotti, F., Arnesen, H., Bachmann, F., Huber, K., et al. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. Thromb Haemost 111 (2014), 781–782.
139. 139 Ruff, C.T., Giugliano, R.P., Braunwald, E., Hoffman, E.B., Deenadayalu, N., Ezekowitz, M.D., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383 (2014), 955–962.
140. 140 De Caterina, R., Husted, S., Wallentin, L., Andreotti, F., Arnesen, H., Bachmann, F., et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis—Task Force on Anticoagulants in Heart Disease Position Paper. J Am Coll Cardiol 59 (2012), 1413–1425.
141. 141 Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.C., Hacke, W., et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17 (2015), 1467–1507.
142. 142 Eriksson, B.I., Quinlan, D.J., Weitz, J.I., Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 48 (2009), 1–22.
143. 143 Lip, G.Y.H., Agnelli, G., Edoxaban: a focused review of its clinical pharmacology. Eur Heart J 35 (2014), 1844–1855.
144. 144 Hohnloser, S.H., Oldgren, J., Yang, S., Wallentin, L., Ezekowitz, M., Reilly, P., et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 125 (2012), 669–676.
145. 145 Uchino, K., Hernandez, A.V., Dabigatran association with higher risk of acute coronary events: Meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 172 (2012), 397–402.
146. 146 Graham, D.J., Reichman, M.E., Wernecke, M., Zhang, R., Southworth, M.R., Levenson, M., et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 131 (2015), 157–164.
147. 147 Deal, E.N., Pope, H., Ross, W., Apixaban use among patients with severe renal impairment. Ann Pharmacother, 48, 2014, 1667.
148. 148 Yamashita, T., Koretsune, Y., Yang, Y., Chen, S.A., Chung, N., Shimada, Y.J., et al. Edoxaban vs. warfarin in East Asian patients with atrial fibrillation—an ENGAGE AF-TIMI 48 subanalysis. Circ J 80 (2016), 860–869.
149. 149 Lip, G.Y., Wang, K.L., Chiang, C.E., Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal. Int J Cardiol 180 (2015), 246–254.
150. 150 Wang, K.L., Lip, G.Y., Lin, S.J., Chiang, C.E., Non-vitamin K antagonist oral anticoagulants for stroke prevention in asian patients with nonvalvular atrial fibrillation: meta-analysis. Stroke 46 (2015), 2555–2561.
151. 151 Hori, M., Matsumoto, M., Tanahashi, N., Momomura, S.I., Uchiyama, S., Goto, S., et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation; the J-ROCKET AF study. Circ J 76 (2012), 2104–2111.
152. 152 Freeman, J.V., Zhu, R.P., Owens, D.K., Garber, A.M., Hutton, D.W., Go, A.S., et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 154 (2011), 1–11.
153. 153 Shah, S.V., Gage, B.F., Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 123 (2011), 2562–2570.
154. 154 Majeed, A., Hwang, H.-G., Connolly, S.J., Eikelboom, J.W., Ezekowitz, M.D., Wallentin, L., et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 128 (2013), 2325–2332.
155. 155 Schiele, F., van Ryn, J., Canada, K., Newsome, C., Sepulveda, E., Park, J., et al. A specific antidote for dabigatran: functional and structural characterization. Blood 121 (2013), 3554–3562.
156. 156 Pollack, C.V., Reilly, P.A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R.A., et al. Idarucizumab for dabigatran reversal. N Engl J Med 373 (2015), 511–520.
157. 157 Lu, G., DeGuzman, F.R., Hollenbach, S.J., Karbarz, M.J., Abe, K., Lee, G., et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 19 (2013), 446–451.
158. 158 Siegal, D.M., Curnutte, J.T., Connolly, S.J., Lu, G., Conley, P.B., Wiens, B.L., et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373 (2015), 2413–2424.
159. 159 Verma, A., Cairns, J.A., Mitchell, L.B., Macle, L., Stiell, I.G., Gladstone, D., et al. 2014 Focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can J Cardiol 30 (2014), 1114–1130.
160. 160 Shimada, Y.J., Yamashita, T., Koretsune, Y., Kimura, T., Abe, K., Sasaki, S., et al. Effects of regional differences in Asia on efficacy and safety of edoxaban compared with warfarin-insights from the ENGAGE AF-TIMI 48 trial. Circ J 79 (2015), 2560–2567.
161. 161 Chao, T.F., Liu, C.J., Wang, K.L., Lin, Y.J., Chang, S.L., Lo, L.W., et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?. J Am Coll Cardiol 65 (2015), 635–642.
162. 162 Chao, T.F., Liu, C.J., Tuan, T.C., Chen, S.J., Wang, K.L., Lin, Y.J., et al. Comparisons of CHADS2 and CHA2DS2-VASc scores for stroke risk stratification in atrial fibrillation: which scoring system should be used for Asians?. Heart Rhythm 13 (2016), 46–53.
163. 163 Lip, G.Y.H., Nielsen, P.B., Should patients with atrial fibrillation and 1 stroke risk factor (CHA2DS2-VASc score 1 in men, 2 in women) be anticoagulated? Yes: even 1 stroke risk factor confers a real risk of stroke. Circulation 133 (2016), 1498–1503.
164. 164 Xiong, Q., Chen, S., Senoo, K., Proietti, M., Hong, K., Lip, G.Y.H., The CHADS2 and CHA2DS2-VASc scores for predicting ischemic stroke among East Asian patients with atrial fibrillation: a systemic review and meta-analysis. Int J Coll Cardiol 195 (2015), 237–242.
165. 165 Kovacs, R.J., Flaker, G.C., Saxonhouse, S.J., Doherty, J.U., Birtcher, K.K., Cuker, A., et al. Practical management of anticoagulation in patients with atrial fibrillation. J Am Coll Cardiol 65 (2015), 1340–1360.
166. 166 Eikelboom, J.W., Wallentin, L., Connolly, S.J., Ezekowitz, M., Healey, J.S., Oldgren, J., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Circulation 123 (2011), 2363–2372.
167. 167 Lip, G.Y., Windecker, S., Huber, K., Kirchhof, P., Marin, F., Ten Berg, J.M., et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 35 (2014), 3155–3179.
168. 168 Oldgren, J., Wallentin, L., Alexander, J.H., James, S., Jönelid, B., Steg, G., et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J 34 (2013), 1670–1680.
169. 169 Dewilde, W.J.M., Oirbans, T., Verheugt, F.W.A., Kelder, J.C., De Smet, B.J.G.L., Herrman, J.P., et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381 (2013), 1107–1115.
170. 170 Dans, A.L., Connolly, S.J., Wallentin, L., Yang, S., Nakamya, J., Brueckmann, M., et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 127 (2013), 634–640.
171. 171 Alexander, J.H., Lopes, R.D., Thomas, L., Alings, M., Atar, D., Aylward, P., et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 35 (2014), 224–232.
172. 172 Lamberts, M., Gislason, G.H., Lip, G.Y.H., Lassen, J.F., Olesen, J.B., Mikkelsen, A.P., et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 129 (2014), 1577–1585.
173. 173 Lip, G.Y.H., Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation. BMJ 336 (2008), 614–615.
174. 174 Diener, H.C., Aisenberg, J., Ansell, J., Atar, D., Breithardt, G., Eikelboom, J., et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. Eur Heart J, 2016 pii: ehv643. [Epub ahead of print].
175. 175 Diener, H.C., Aisenberg, J., Ansell, J., Atar, D., Breithardt, G., Eikelboom, J., et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J, 2016 pii: ehw069. [Epub ahead of print].
176. 176 Ntaios, G., Papavasileiou, V., Diener, H.C., Makaritsis, K., Michel, P., Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke 43 (2012), 3298–3304.
177. 177 Flaker, G.C., Gruber, M., Connolly, S.J., Goldman, S., Chaparro, S., Vahanian, A., et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: An exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 152 (2006), 967–973.
178. 178 Rådberg, J.A., Olsson, J.E., Rådberg, C.T., Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment. Stroke 22 (1991), 571–576.
179. 179 Hart, R.G., Diener, H.C., Yang, S., Connolly, S.J., Wallentin, L., Reilly, P.A., et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 43 (2012), 1511–1517.
180. 180 Xian, Y., Liang, L., Smith, E.E., Schwamm, L.H., Reeves, M.J., Olson, D.M., et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA 307 (2012), 2600–2608.
181. 181 Nielsen, P.B., Larsen, T.B., Skjøth, F., Gorst-Rasmussen, A., Rasmussen, L.H., Lip, G.Y.H., Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. Circulation 132 (2015), 517–525.
182. 182 Kuramatsu, J.B., Gerner, S.T., Schellinger, P.D., Glahn, J., Endres, M., Sobesky, J., et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 313 (2015), 824–836.
183. 183 Chao, T.F., Liu, C.J., Liao, J.N., Wang, K.L., Lin, Y.J., Chang, S.L., et al. The use of oral anticoagulants for stroke prevention in atrial fibrillation patients with history of intra-cranial hemorrhage. Circulation 133 (2016), 1540–1547.
184. 184 Chiang, C.E., Wang, T.D., Li, Y.H., Lin, T.H., Chien, K.L., Yeh, H.I., et al. 2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension. J Formos Med Assoc 109 (2010), 740–773.
185. 185 Siegal, D., Yudin, J., Kaatz, S., Douketis, J.D., Lim, W., Spyropoulos, A.C., Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 126 (2012), 1630–1639.
186. 186 Rechenmacher, S.J., Fang, J.C., Bridging anticoagulation: primum non nocere. J Am Coll Cardiol 66 (2015), 1392–1403.
187. 187 Douketis, J.D., Spyropoulos, A.C., Kaatz, S., Becker, R.C., Caprini, J.A., Dunn, A.S., et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 373 (2015), 823–833.
188. 188 Spyropoulos, A.C., Douketis, J.D., How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 120 (2012), 2954–2962.
189. 189 Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15 (2013), 625–651.
190. 190 Nagarakanti, R., Ezekowitz, M.D., Oldgren, J., Yang, S., Chernick, M., Aikens, T.H., et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 123 (2011), 131–136.
191. 191 Flaker, G., Lopes, R.D., Al-Khatib, S.M., Hermosillo, A.G., Hohnloser, S.H., Tinga, B., et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol 63 (2014), 1082–1087.
192. 192 Piccini, J.P., Stevens, S.R., Lokhnygina, Y., Patel, M.R., Halperin, J.L., Singer, D.E., et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol 61 (2013), 1998–2006.
193. 193 Cappato, R., Ezekowitz, M.D., Klein, A.L., Camm, A.J., Ma, C.S., Le Heuzey, J.Y., et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 35 (2014), 3346–3355.
194. 194 Weitz, J.I., Healey, J.S., Skanes, A.C., Verma, A., Periprocedural management of new oral anticoagulants in patients undergoing atrial fibrillation ablation. Circulation 129 (2014), 1688–1694.
195. 195 Calkins, H., Kuck, K.H., Cappato, R., Brugada, J., Camm, A.J., Chen, S.A., et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 14 (2012), 528–606.
196. 196 Cappato, R., Calkins, H., Chen, S.A., Davies, W., Iesaka, Y., Kalman, J., et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 3 (2010), 32–38.
197. 197 Sticherling, C., Marin, F., Birnie, D., Boriani, G., Calkins, H., Dan, G.A., et al. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace 17 (2015), 1197–1214.
198. 198 Di Biase, L., Burkhardt, J.D., Santangeli, P., Mohanty, P., Sanchez, J.E., Horton, R., et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation 129 (2014), 2638–2644.
199. 199 Hohnloser, S.H., Camm, A.J., Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Europace 15 (2013), 1407–1411.
200. 200 Di Biase, L., Lakkireddy, D., Trivedi, C., Deneke, T., Martinek, M., Mohanty, S., et al. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study. Heart Rhythm 12 (2015), 1162–1168.
201. 201 Lakkireddy, D., Reddy, Y.M., Di Biase, L., Vallakati, A., Mansour, M.C., Santangeli, P., et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 63 (2014), 982–988.
202. 202 Cappato, R., Marchlinski, F.E., Hohnloser, S.H., Naccarelli, G.V., Xiang, J., Wilber, D.J., et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 36 (2015), 1805–1811.
203. 203 Karasoy, D., Gislason, G.H., Hansen, J., Johannessen, A., Køber, L., Hvidtfeldt, M., et al. Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of Denmark. Eur Heart J 36 (2015), 307–315.
204. 204 Wilson, D., Charidimou, A., Shakeshaft, C., Ambler, G., White, M., Cohen, H., et al. Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type. Neurology 86 (2016), 360–366.
205. 205 Piccini, J.P., Hellkamp, A.S., Washam, J.B., Becker, R.C., Breithardt, G., Berkowitz, S.D., et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation 133 (2016), 352–360.
206. 206 Klein, A.L., Grimm, R.A., Murray, R.D., Apperson-Hansen, C., Asinger, R.W., Black, I.W., et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 344 (2001), 1411–1420.
207. 207 Dawson, A.G., Asopa, S., Dunning, J., Should patients undergoing cardiac surgery with atrial fibrillation have left atrial appendage exclusion?. Interact Cardiovasc Thorac Surg 10 (2010), 306–311.
208. 208 Holmes, D.R., Reddy, V.Y., Turi, Z.G., Doshi, S.K., Sievert, H., Buchbinder, M., et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 374 (2009), 534–542.
209. 209 Reddy, V.Y., Holmes, D., Doshi, S.K., Neuzil, P., Kar, S., Safety of percutaneous left atrial appendage closure: results from the watchman left atrial appendage system for embolic protection in patients with AF (PROTECT AF) clinical trial and the continued access registry. Circulation 123 (2011), 417–424.
210. 210 Holmes, D.R. Jr., Kar, S., Price, M.J., Whisenant, B., Sievert, H., Doshi, S.K., et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 64 (2014), 1–12.
211. 211 Bartus, K., Han, F.T., Bednarek, J., Myc, J., Kapelak, B., Sadowski, J., et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J Am Coll Cardiol 62 (2013), 108–118.
212. 212 de Denus, S., Sanoski, C.A., Carlsson, J., Opolski, G., Spinler, S.A., Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med 165 (2005), 258–262.
213. 213 Corley, S.D., Epstein, A.E., diMarco, J.P., Domanski, M.J., Geller, N., Greene, H.L., et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation 109 (2004), 1509–1513.
214. 214 Wyse, D.G., Waldo, A.L., DiMarco, J.P., Domanski, M.J., Rosenberg, Y., Schron, E.B., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (2002), 1825–1833.
215. 215 Singh, B.N., Singh, S.N., Reda, D.J., Tang, X.C., Lopez, B., Harris, C.L., et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 352 (2005), 1861–1872.
216. 216 Hagens, V.E., Ranchor, A.V., Van Sonderen, E., Bosker, H.A., Kamp, O., Tijssen, J.G.P., et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation: results from the Rate Control versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol 43 (2004), 241–247.
217. 217 Kirchhof, P., Bax, J., Blomstrom-Lundquist, C., Calkins, H., Camm, A.J., Cappato, R., et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference ‘research perspectives in AF’. Eur Heart J, 30, 2009 2969–77c.
218. 218 Van Gelder, I.C., Haegeli, L.M., Brandes, A., Heidbuchel, H., Aliot, E., Kautzner, J., et al. Rationale and current perspective for early rhythm control therapy in atrial fibrillation. Europace 13 (2011), 1517–1525.
219. 219 Ogawa, S., Yamashita, T., Yamazaki, T., Aizawa, Y., Atarashi, H., Inoue, H., et al. Optimal Treatment Strategy for Patients With Paroxysmal Atrial Fibrillation:J-RHYTHM Study. Circ J 73 (2009), 242–248.
220. 220 Lown, B., Electrical reversion of cardiac arrhythmias. Br Heart J 29 (1967), 469–489.
221. 221 Stiell, I.G., Macle, L., Canadian Cardiovascular Society atrial fibrillation guidelines 2010: management of recent-onset atrial fibrillation and flutter in the emergency department. Can J Cardiol 27 (2011), 38–46.
222. 222 Hou, Z.Y., Chang, M.S., Chen, C.Y., Tu, M.S., Lin, S.L., Chiang, H.T., et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J 16 (1995), 521–528.
223. 223 Badshah, A., Mirza, B., Janjua, M., Nair, R., Steinman, R.T., Cotant, J.F., Amiodarone-induced torsade de pointes in a patient with Wolff–Parkinson–White syndrome. Hellenic J Cardiol 50 (2009), 224–226.
224. 224 Nebojša, M., Dragan, S., Nebojša, A., Tamara, A., Lethal outcome after intravenous administration of amiodarone in patient with atrial fibrillation and ventricular preexcitation. J Cardiovasc Electrophysiol 22 (2011), 1077–1078.
225. 225 Gulamhusein, S., Ko, P., Carruthers, S.G., Klein, G.J., Acceleration of the ventricular response during atrial fibrillation in the Wolff–Parkinson–White syndrome after verapamil. Circulation 65 (1982), 348–354.
226. 226 Dorian, P., Connors, S.P., Pharmacological and nonpharmacological methods for rate control. Can J Cardiol 21:Suppl B (2005), 26B–30B.
227. 227 Tsuneda, T., Yamashita, T., Fukunami, M., Kumagai, K., Niwano, S.I., Okumura, K., et al. Rate control and quality of life in patients with permanent atrial fibrillation: the Quality Of Life and Atrial Fibrillation (QOLAF) study. Circ J 70 (2006), 965–970.
228. 228 Farshi, R., Kistner, D., Sarma, J.S., Longmate, J.A., Singh, B.N., Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 33 (1999), 304–310.
229. 229 David, D., Segni, E.D., Klein, H.O., Kaplinsky, E., Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added β adrenergic blocking agent. Am J Cardiol 44 (1979), 1378–1382.
230. 230 Chao, T.F., Liu, C.J., Tuan, T.C., Chen, S.J., Wang, K.L., Lin, Y.J., et al. Rate-control treatment and mortality in atrial fibrillation. Circulation 132 (2015), 1604–1612.
231. 231 Chao, T.F., Liu, C.J., Chen, S.J., Wang, K.L., Lin, Y.J., Chang, S.L., et al. Does digoxin increase the risk of ischemic stroke and mortality in atrial fibrillation? A nationwide population-based cohort study. Can J Cardiol 30 (2014), 1190–1195.
232. 232 Chang, S.S., Chang, K.C., Wang, Y.C., Muo, C.H., Pai, P.Y., Chang, C.B., et al. Digoxin use is associated with increased risk of stroke in patients with non-valvular atrial fibrillation—a nationwide population-based cohort study. Int J Cardiol 169 (2013), e26–e27.
233. 233 Washam, J.B., Stevens, S.R., Lokhnygina, Y., Halperin, J.L., Breithardt, G., Singer, D.E., et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet 385 (2015), 2363–2370.
234. 234 Whitbeck, M.G., Charnigo, R.J., Khairy, P., Ziada, K., Bailey, A.L., Zegarra, M.M., et al. Increased mortality among patients taking digoxin—analysis from the AFFIRM study. Eur Heart J 34 (2013), 1481–1488.
235. 235 Chen, Y., Cai, X., Huang, W., Wu, Y., Huang, Y., Hu, Y., Increased all-cause mortality associated with digoxin therapy in patients with atrial fibrillation: an updated meta-analysis. Medicine (Baltimore), 94, 2015, e2409.
236. 236 Grogan, M., Smith, H.C., Gersh, B.J., Wood, D.L., Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 69 (1992), 1570–1573.
237. 237 Packer, D.L., Bardy, G.H., Worley, S.J., Smith, M.S., Cobb, F.R., Coleman, R.E., et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 57 (1986), 563–570.
238. 238 Van Gelder, I.C., Wyse, D.G., Chandler, M.L., Cooper, H.A., Olshansky, B., Hagens, V.E., et al. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace 8 (2006), 935–942.
239. 239 Van Gelder, I.C., Groenveld, H.F., Crijns, H.J., Tuininga, Y.S., Tijssen, J.G., Alings, A.M., et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 362 (2010), 1363–1373.
240. 240 Groenveld, H.F., Tijssen, J.G.P., Crijns, H.J.G.M., Van den Berg, M.P., Hillege, H.L., Alings, M., et al. Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation). J Am Coll Cardiol 61 (2013), 741–748.
241. 241 Khan, M.N., Jaïs, P., Cummings, J., Di Biase, L., Sanders, P., Martin, D.O., et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 359 (2008), 1778–1785.
242. 242 Hernández-Madrid, A., Svendsen, J.H., Lip, G.Y.H., Van Gelder, I.C., Dobreanu, D., Blomstrom-Lundqvist, C., Cardioversion for atrial fibrillation in current European practice: results of the European Heart Rhythm Association survey. Europace 15 (2013), 915–918.
243. 243 Van Gelder, I.C., Hagens, V.E., Bosker, H.A., Kingma, J.H., Kamp, O., Kingma, T., et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347 (2002), 1834–1840.
244. 244 Carlsson, J., Miketic, S., Windeler, J., Cuneo, A., Haun, S., Micus, S., et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 41 (2003), 1690–1696.
245. 245 Opolski, G., Torbicki, A., Kosior, D.A., Szulc, M., Wozakowska-Kaplon, B., Kolodziej, P., et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 126 (2004), 476–486.
246. 246 Airaksinen, K.E.J., Grönberg, T., Nuotio, I., Nikkinen, M., Ylitalo, A., Biancari, F., et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol 62 (2013), 1187–1192.
247. 247 Gall, N.P., Murgatroyd, F.D., Electrical cardioversion for AF—the state of the art. Pacing Clin Electrophysiol 30 (2007), 554–567.
248. 248 Page, R.L., Kerber, R.E., Russell, J.K., Trouton, T., Waktare, J., Gallik, D., et al. Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial. J Am Coll Cardiol 39 (2002), 1956–1963.
249. 249 Botto, G.L., Politi, A., Bonini, W., Broffoni, T., Bonatti, R., External cardioversion of atrial fibrillation: role of paddle position on technical efficacy and energy requirements. Heart 82 (1999), 726–730.
250. 250 Boriani, G., Biffi, M., Capucci, A., Botto, G., Broffoni, T., Ongari, M., et al. Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols. Pacing Clin Electrophysiol. 21 (1998), 2470–2474.
251. 251 Naccarelli, G.V., Wolbrette, D.L., Khan, M., Bhatta, L., Hynes, J., Samii, S., et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol 91 (2003), 15–26.
252. 252 Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 321 (1989), 406–412.
253. 253 Lafuente-Lafuente, C., Mouly, S., Longas-Tejero, M.A., Mahe, I., Bergmann, J.F., Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 166 (2006), 719–728.
254. 254 Coplen, S.E., Antman, E.M., Berlin, J.A., Hewitt, P., Chalmers, T.C., Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 82 (1990), 1106–1116.
255. 255 Lafuente-Lafuente, C., Mouly, S., Longas-Tejero, M.A., Bergmann, J.F., Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev, 2007, 2007, CD005049.
256. 256 Roy, D., Talajic, M., Dorian, P., Connolly, S., Eisenberg, M.J., Green, M., et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 342 (2000), 913–920.
257. 257 Freemantle, N., Lafuente-Lafuente, C., Mitchell, S., Eckert, L., Reynolds, M., Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 13 (2011), 329–345.
258. 258 Doyle, J.F., Ho, K.M., Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis. Mayo Clin Proc 84 (2009), 234–242.
259. 259 Bardy, G.H., Lee, K.L., Mark, D.B., Poole, J.E., Packer, D.L., Boineau, R., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005), 225–237.
260. 260 Connolly, S.J., Evidence-based analysis of amiodarone efficacy and safety. Circulation 100 (1999), 2025–2034.
261. 261 Singh, B.N., Connolly, S.J., Crijns, H.J.G.M., Roy, D., Kowey, P.R., Capucci, A., et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 357 (2007), 987–999.
262. 262 Le Heuzey, J.Y., De Ferrari, G.M., Radzik, D., Santini, M., Zhu, J., Davy, J.M., A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The DIONYSOS Study. J Cardiovasc Electrophysiol 21 (2010), 597–605.
263. 263 Hohnloser, S.H., Crijns, H.J.G.M., van Eickels, M., Gaudin, C., Page, R.L., Torp-Pedersen, C., et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360 (2009), 668–678.
264. 264 Connolly, S.J., Crijns, H.J.G.M., Torp-Pedersen, C., van Eickels, M., Gaudin, C., Page, R.L., et al. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation 120 (2009), 1174–1180.
265. 265 Kober, L., Torp-Pedersen, C., McMurray, J.J.V., Gotzsche, O., Levy, S., Crijns, H., et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 358 (2008), 2678–2687.
266. 266 Connolly, S.J., Camm, A.J., Halperin, J.L., Joyner, C., Alings, M., Amerena, J., et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 365 (2011), 2268–2276.
267. 267 Alboni, P., Botto, G.L., Baldi, N., Luzi, M., Russo, V., Gianfranchi, L., et al. Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach. N Engl J Med 351 (2004), 2384–2391.
268. 268 Khan, I.A., Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol 37 (2001), 542–547.
269. 269 Wachtell, K., Lehto, M., Gerdts, E., Olsen, M.H., Hornestam, B., Dahlof, B., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45 (2005), 712–719.
270. 270 Schneider, M.P., Hua, T.A., Böhm, M., Wachtell, K., Kjeldsen, S.E., Schmieder, R.E., Prevention of atrial fibrillation by renin-angiotensin system inhibition: a meta-analysis. J Am Coll Cardiol 55 (2010), 2299–2307.
271. 271 Savelieva, I., Kakouros, N., Kourliouros, A., Camm, A.J., Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace 13 (2011), 308–328.
272. 272 GISSI-AF Investigators, Disertori, M., Latini, R., Barlera, S., Franzosi, M.G., Staszewsky, L., et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360 (2009), 1606–1617.
273. 273 Yamashita, T., Inoue, H., Okumura, K., Kodama, I., Aizawa, Y., Atarashi, H., et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace 13 (2011), 473–479.
274. 274 Goette, A., Schön, N., Kirchhof, P., Breithardt, G., Fetsch, T., Häusler, K.G., et al. Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol 5 (2012), 43–51.
275. 275 Patti, G., Chello, M., Candura, D., Pasceri, V., D'Ambrosio, A., Covino, E., et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 114 (2006), 1455–1461.
276. 276 Liakopoulos, O.J., Choi, Y.H., Kuhn, E.W., Wittwer, T., Borys, M., Madershahian, N., et al. Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review. J Thorac Cardiovasc Surg, 138, 2009 678–86.e671.
277. 277 Maggioni, A.P., Fabbri, G., Lucci, D., Marchioli, R., Franzosi, M.G., Latini, R., et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J 30 (2009), 2327–2336.
278. 278 Savelieva, I., Kourliouros, A., Camm, J., Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. Naunyn Schmiedebergs Arch Pharmacol 381 (2010), 1–13.
279. 279 Sakabe, M., Shiroshita-Takeshita, A., Maguy, A., Dumesnil, C., Nigam, A., Leung, T.K., et al. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation 116 (2007), 2101–2109.
280. 280 Sarrazin, J.F., Comeau, G., Daleau, P., Kingma, J., Plante, I., Fournier, D., et al. Reduced incidence of vagally induced atrial fibrillation and expression levels of connexins by n-3 polyunsaturated fatty acids in dogs. J Am Coll Cardiol 50 (2007), 1505–1512.
281. 281 Kowey, P.R., Reiffel, J.A., Ellenbogen, K.A., Naccarelli, G.V., Pratt, C.M., Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA 304 (2010), 2363–2372.
282. 282 Mozaffarian, D., Marchioli, R., Macchia, A., et al. Fish oil and postoperative atrial fibrillation: The omega-3 fatty acids for prevention of post-operative atrial fibrillation (opera) randomized trial. JAMA 308 (2012), 2001–2011.
283. 283 Macchia, A., Grancelli, H., Varini, S., Nul, D., Laffaye, N., Mariani, J., et al. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) Trial. J Am Coll Cardiol 61 (2013), 463–468.
284. 284 Mariani, J., Doval, H.C., Nul, D., Varini, S., Grancelli, H., Ferrante, D., et al. N-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc, 2, 2013, e005033.
285. 285 Russo, C., Jin, Z., Homma, S., Rundek, T., Elkind, M.S.V., Sacco, R.L., et al. Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort. J Am Coll Cardiol 57 (2011), 1368–1374.
286. 286 Visser, M., Bouter, L.M., McQuillan, G.M., Wener, M.H., Harris, T.B., ELevated c-reactive protein levels in overweight and obese adults. JAMA 282 (1999), 2131–2135.
287. 287 Stritzke, J., Markus, M.R.P., Duderstadt, S., Lieb, W., Luchner, A., Döring, A., et al. The aging process of the heart: obesity is the main risk factor for left atrial enlargement during aging: the MONICA/KORA (Monitoring of Trends and Determinations in Cardiovascular Disease/Cooperative Research in the Region of Augsburg) study. J Am Coll Cardiol 54 (2009), 1982–1989.
288. 288 Wong, C.X., Abed, H.S., Molaee, P., Nelson, A.J., Brooks, A.G., Sharma, G., et al. Pericardial fat is associated with atrial fibrillation severity and ablation outcome. J Am Coll Cardiol 57 (2011), 1745–1751.
289. 289 Abed, H.S., Wittert, G.A., Leong, D.P., Shirazi, M.G., Bahrami, B., Middeldorp, M.E., et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: A randomized clinical trial. JAMA 310 (2013), 2050–2060.
290. 290 Pathak, R.K., Middeldorp, M.E., Meredith, M., Mehta, A.B., Mahajan, R., Wong, C.X., et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol 65 (2015), 2159–2169.
291. 291 Pathak, R.K., Middeldorp, M.E., Lau, D.H., Mehta, A.B., Mahajan, R., Twomey, D., et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol 64 (2014), 2222–2231.
292. 292 Kodama, S., Saito, K., Tanaka, S., Maki, M., Yachi, Y., Asumi, M., et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: A meta-analysis. JAMA 301 (2009), 2024–2035.
293. 293 Huxley, R.R., Misialek, J.R., Agarwal, S.K., Loehr, L.R., Soliman, E.Z., Chen, L.Y., et al. Physical activity, obesity, weight change, and risk of atrial fibrillation: the atherosclerosis risk in communities study. Circ Arrhythm Electrophysiol 7 (2014), 620–625.
294. 294 Pathak, R.K., Elliott, A., Middeldorp, M.E., Meredith, M., Mehta, A.B., Mahajan, R., et al. Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study. J Am Coll Cardiol 66 (2015), 985–996.
295. 295 Qureshi, W.T., Alirhayim, Z., Blaha, M.J., Juraschek, S.P., Keteyian, S.J., Brawner, C.A., et al. Cardiorespiratory fitness and risk of incident atrial fibrillation: results from the Henry Ford exercise testing (FIT) project. Circulation 131 (2015), 1827–1834.
296. 296 Pappone, C., Rosanio, S., Augello, G., Gallus, G., Vicedomini, G., Mazzone, P., et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 42 (2003), 185–197.
297. 297 Wazni, O.M., Marrouche, N.F., Martin, D.O., Verma, A., Bhargava, M., Saliba, W., et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 293 (2005), 2634–2640.
298. 298 Oral, H., Pappone, C., Chugh, A., Good, E., Bogun, F., Pelosi, F. Jr., et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 354 (2006), 934–941.
299. 299 Pappone, C., Augello, G., Sala, S., Gugliotta, F., Vicedomini, G., Gulletta, S., et al. A Randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF study. J Am Coll Cardiol 48 (2006), 2340–2347.
300. 300 Stabile, G., Bertaglia, E., Senatore, G., De Simone, A., Zoppo, F., Donnici, G., et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 27 (2006), 216–221.
301. 301 Jais, P., Cauchemez, B., Macle, L., Daoud, E., Khairy, P., Subbiah, R., et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 118 (2008), 2498–2505.
302. 302 Wilber, D.J., Pappone, C., Neuzil, P., de Paola, A., Marchlinski, F., Natale, A., et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 303 (2010), 333–340.
303. 303 Mont, L., Bisbal, F., Hernández-Madrid, A., Pérez-Castellano, N., Viñolas, X., Arenal, A., et al. Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). Eur Heart J 35 (2014), 501–507.
304. 304 Tsao, H.M., Hu, W.C., Wu, M.H., Tai, C.T., Chang, S.L., Lin, Y.J., et al. The impact of catheter ablation on the dynamic function of the left atrium in patients with atrial fibrillation: insights from four-dimensional computed tomographic images. J Cardiovasc Electrophysiol 21 (2010), 270–277.
305. 305 Nademanee, K., Schwab, M.C., Kosar, E.M., Karwecki, M., Moran, M.D., Visessook, N., et al. Clinical outcomes of catheter substrate ablation for high-risk patients with atrial fibrillation. J Am Coll Cardiol 51 (2008), 843–849.
306. 306 Cleland, J.G.F., Coletta, A.P., Buga, L., Ahmed, D., Clark, A.L., Clinical trials update from the American College of Cardiology meeting 2010: DOSE, ASPIRE, CONNECT, STICH, STOP-AF, CABANA, RACE II, EVEREST II, ACCORD, and NAVIGATOR. Eur J Heart Fail 12 (2010), 623–629.
307. 307 Chao, T.F., Tsao, H.M., Lin, Y.J., Tsai, C.F., Lin, W.S., Chang, S.L., et al. Clinical outcome of catheter ablation in patients with nonparoxysmal atrial fibrillation: results of 3-year follow-up. Circ Arrhythm Electrophysiol 5 (2012), 514–520.
308. 308 Chen, S.A., Hsieh, M.H., Tai, C.T., Tsai, C.F., Prakash, V.S., Yu, W.C., et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 100 (1999), 1879–1886.
309. 309 Dagres, N., Bongiorni, M.G., Larsen, T.B., Hernandez-Madrid, A., Pison, L., Blomström-Lundqvist, C., et al. Current ablation techniques for persistent atrial fibrillation: results of the European Heart Rhythm Association Survey. Europace 17 (2015), 1596–1600.
310. 310 Gerstenfeld, E.P., Dixit, S., Callans, D., Rho, R., Rajawat, Y., Zado, E., et al. Utility of exit block for identifying electrical isolation of the pulmonary veins. J Cardiovasc Electrophysiol 13 (2002), 971–979.
311. 311 Arentz, T., Weber, R., Bürkle, G., Herrera, C., Blum, T., Stockinger, J., et al. Small or large isolation areas around the pulmonary veins for the treatment of atrial fibrillation? Results from a prospective randomized study. Circulation 115 (2007), 3057–3063.
312. 312 Lo, L.W., Tai, C.T., Lin, Y.J., Chang, S.L., Wongcharoen, W., Hsieh, M.H., et al. Mechanisms of recurrent atrial fibrillation: comparisons between segmental ostial versus circumferential pulmonary vein isolation. J Cardiovasc Electrophysiol 18 (2007), 803–807.
313. 313 Lin, W.S., Tai, C.T., Hsieh, M.H., Tsai, C.F., Lin, Y.K., Tsao, H.M., et al. Catheter ablation of paroxysmal atrial fibrillation initiated by non–pulmonary vein ectopy. Circulation 107 (2003), 3176–3183.
314. 314 Lin, Y.J., Tai, C.T., Kao, T., Tso, H.W., Huang, J.L., Higa, S., et al. Electrophysiological characteristics and catheter ablation in patients with paroxysmal right atrial fibrillation. Circulation 112 (2005), 1692–1700.
315. 315 Atienza, F., Almendral, J., Jalife, J., Zlochiver, S., Ploutz-Snyder, R., Torrecilla, E.G., et al. Real-time dominant frequency mapping and ablation of dominant frequency sites in atrial fibrillation with left-to-right frequency gradients predicts long-term maintenance of sinus rhythm. Heart Rhythm 6 (2009), 33–40.
316. 316 Chang, S.L., Lin, Y.J., Tai, C.T., Lo, L.W., Tuan, T.C., Udyavar, A.R., et al. Induced atrial tachycardia after circumferential pulmonary vein isolation of paroxysmal atrial fibrillation: electrophysiological characteristics and impact of catheter ablation on the follow-up results. J Cardiovasc Electrophysiol 20 (2009), 388–394.
317. 317 Haïssaguerre, M., Hocini, M., Sanders, P., Sacher, F., Rotter, M., Takahashi, Y., et al. Catheter ablation of long-lasting persistent atrial fibrillation: clinical outcome and mechanisms of subsequent arrhythmias. J Cardiovasc Electrophysiol 16 (2005), 1138–1147.
318. 318 Lin, Y.J., Tai, C.T., Chang, S.L., Lo, L.W., Tuan, T.C., Wongcharoen, W., et al. Efficacy of additional ablation of complex fractionated atrial electrograms for catheter ablation of nonparoxysmal atrial fibrillation. J Cardiovasc Electrophysiol 20 (2009), 607–615.
319. 319 Lin, Y.J., Lo, M.T., Lin, C., Chang, S.L., Lo, L.W., Hu, Y.F., et al. Prevalence, characteristics, mapping, and catheter ablation of potential rotors in nonparoxysmal atrial fibrillation. Circ Arrhythm Electrophysiol 6 (2013), 851–858.
320. 320 Verma, A., Jiang, C.Y., Betts, T.R., Chen, J., Deisenhofer, I., Mantovan, R., et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med 372 (2015), 1812–1822.
321. 321 Natale, A., Newby, K.H., Pisanó, E., Leonelli, F., Fanelli, R., Potenza, D., et al. Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol 35 (2000), 1898–1904.
322. 322 Hsieh, M.H., Tai, C.T., Chiang, C.E., Tsai, C.F., Yu, W.C., Chen, Y.J., et al. Recurrent atrial flutter and atrial fibrillation after catheter ablation of the cavotricuspid isthmus: a very long-term follow-up of 333 patients. J Interv Card Electrophysiol 7 (2002), 225–231.
323. 323 Lin, Y.J., Chao, T.F., Tsao, H.M., Chang, S.L., Lo, L.W., Chiang, C.E., et al. Successful catheter ablation reduces the risk of cardiovascular events in atrial fibrillation patients with CHA2DS2-VASc risk score of 1 and higher. Europace 15 (2013), 676–684.
324. 324 Chao, T.F., Lin, Y.J., Tsao, H.M., Tsai, C.F., Lin, W.S., Chang, S.L., et al. CHADS2 and CHA2DS2-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation. J Am Coll Cardiol 58 (2011), 2380–2385.
325. 325 Izumoto, H., Kawazoe, K., Eishi, K., Kamata, J., Medium-term results after the modified Cox/Maze procedure combined with other cardiac surgery. Eur J Cardiothorac Surg 17 (2000), 25–29.
326. 326 McCarthy, P.M., Gillinov, A.M., Castle, L., Chung, M., Cosgrove, D. 3rd, The Cox–Maze procedure: the Cleveland Clinic experience. Semin Thorac Cardiovasc Surg 12 (2000), 25–29.
327. 327 Schaff, H.V., Dearani, J.A., Daly, R.C., Orszulak, T.A., Danielson, G.K., Cox–Maze procedure for atrial fibrillation: Mayo Clinic experience. Semin Thorac Cardiovasc Surg 12 (2000), 30–37.
328. 328 Je, H.G., Lee, J.W., Jung, S.H., Choo, S.J., Song, H., Yun, S.C., et al. Risk factors analysis on failure of maze procedure: mid-term results. Eur J Cardiothorac Surg 36 (2009), 272–279.
329. 329 Weimar, T., Schena, S., Bailey, M.S., Maniar, H.S., Schuessler, R.B., Cox, J.L., et al. The Cox–Maze procedure for lone atrial fibrillation: a single-center experience over 2 decades. Circ Arrhythm Electrophysiol 5 (2012), 8–14.
330. 330 Singer, D.E., Hellkamp, A.S., Piccini, J.P., Mahaffey, K.W., Lokhnygina, Y., Pan, G., et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc, 2, 2013, e000067.
331. 331 Schulman, S., Carrier, M., Lee, A.Y.Y., Shivakumar, S., Blostein, M., Spencer, F.A., et al. Perioperative management of dabigatran: a prospective cohort study. Circulation 132 (2015), 167–173.